These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 33357482)

  • 21. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
    Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
    Stadtmauer EA; Pasquini MC; Blackwell B; Hari P; Bashey A; Devine S; Efebera Y; Ganguly S; Gasparetto C; Geller N; Horowitz MM; Koreth J; Knust K; Landau H; Brunstein C; McCarthy P; Nelson C; Qazilbash MH; Shah N; Vesole DH; Vij R; Vogl DT; Giralt S; Somlo G; Krishnan A
    J Clin Oncol; 2019 Mar; 37(7):589-597. PubMed ID: 30653422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
    O'Donnell E; Mo C; Yee AJ; Nadeem O; Laubach J; Rosenblatt J; Munshi N; Midha S; Cirstea D; Chrysafi P; Horick N; Richardson PG; Raje N
    Lancet Haematol; 2024 Jun; 11(6):e415-e424. PubMed ID: 38677302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
    Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
    Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
    Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
    Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
    Kauer J; Freundt EP; Schmitt A; Weinhold N; Mai EK; Müller-Tidow C; Goldschmidt H; Raab MS; Kriegsmann K; Sauer S
    BMC Cancer; 2023 Nov; 23(1):1132. PubMed ID: 37990162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
    Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J
    Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
    Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Zweegman S; Caillon H; Caillot D; Avet-Loiseau H; Delforge M; Dejoie T; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Schiano de Colella JM; van de Donk NW; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Hua W; Wang J; Tuozzo A; de Boer C; Rowe M; Vanquickelberghe V; Carson R; Vermeulen J; Corre J; Sonneveld P;
    Lancet Oncol; 2024 Aug; 25(8):1003-1014. PubMed ID: 38889735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
    Grosicki S; Simonova M; Spicka I; Pour L; Kriachok I; Gavriatopoulou M; Pylypenko H; Auner HW; Leleu X; Doronin V; Usenko G; Bahlis NJ; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Gironella M; Jurczyszyn A; Robak P; Galli M; Wallington-Beddoe C; Radinoff A; Salogub G; Stevens DA; Basu S; Liberati AM; Quach H; Goranova-Marinova VS; Bila J; Katodritou E; Oliynyk H; Korenkova S; Kumar J; Jagannath S; Moreau P; Levy M; White D; Gatt ME; Facon T; Mateos MV; Cavo M; Reece D; Anderson LD; Saint-Martin JR; Jeha J; Joshi AA; Chai Y; Li L; Peddagali V; Arazy M; Shah J; Shacham S; Kauffman MG; Dimopoulos MA; Richardson PG; Delimpasi S
    Lancet; 2020 Nov; 396(10262):1563-1573. PubMed ID: 33189178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Hockaday A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ;
    Lancet Oncol; 2019 Jan; 20(1):57-73. PubMed ID: 30559051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
    van de Donk NWCJ; Minnema MC; van der Holt B; Schjesvold F; Wu KL; Broijl A; Roeloffzen WWH; Gadisseur A; Pietrantuono G; Pour L; van der Velden VHJ; Lund T; Offidani M; Grasso M; Giaccone L; Razawy W; Tacchetti P; Mancuso K; Silkjaer T; Caers J; Zweegman S; Hájek R; Benjamin R; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P
    Lancet Oncol; 2023 Oct; 24(10):1119-1133. PubMed ID: 37717583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.